Cognixion Receives FDA Breakthrough Device Designation for its Brain-Computer Interface with Augmented Reality for Assistive Communication
U.S. FDA Breakthrough Device designations are granted to expedite the review of technologies with the potential to greatly impact those suffering from life threatening and debilitating diseases.
Cognixion ONE Axon aims to become the first FDA cleared device allowing fully paralyzed or locked-in patients to communicate via a noninvasive brain-computer interface.
With Breakthrough Device designation, Cognixion ONE Axon could become available sooner to help those most in need.
Cognixion ONE is the first and only wireless brain computer interface, integrated with augmented reality in one system
Cognixion®, a leading developer of noninvasive Brain-Computer Interface (BCI) and Augmented Reality (AR) technology, announced today that its flagship device, the Cognixion ONE™ Axon, has been granted U.S. Food and Drug Administration (FDA) Breakthrough Device designation. The designation will allow the company to streamline their development and validation process with prioritized interactive feedback from FDA review staff in preparation for regulatory submission. This special FDA Breakthrough designation is awarded to devices that demonstrate the potential to provide more effective treatment of life-threatening or irreversibly debilitating diseases or conditions for which no clear alternatives exist.
The Cognixion ONE is a revolutionary assisted reality device — the bionic combination or AI, Augmented Reality and Assistive Technology — designed to help people with severe motor impairments communicate and interact more effectively and independently with the world around them. The device utilizes electroencephalogram (EEG) technology to provide a noninvasive brain-computer interface (BCI) enabling patients with advanced disease progression to communicate their responses with their thoughts and mental attention in a wearable, augmented reality headset. Integrating Artificial Intelligence (AI) such as GPT large language models that run on the device with contextual predictions, the device aims to rapidly support the user’s communication intentions and desired outcomes, providing suggestions that can be quickly selected and communicated audibly and visually on the front visor as a communication aid.
The device has been specifically designed to help individuals with neurodegenerative conditions such as Amyotrophic Lateral Sclerosis, also known as ALS or Lou Gehrig’s disease and MND (Motor Neuron Disease) as well as acquired conditions such as traumatic injuries and cerebral palsy that result in severe motor impairments. At present, no such cleared device exists which can allow fully paralyzed or locked-in patients to communicate once the current standard of care, eye-tracking, is no longer usable for their disease state due to ocular motor decline.
"This FDA Breakthrough Device designation is a significant milestone, and we are thrilled to receive it for our Cognixion ONE device," said Andreas Forsland, CEO and Founder of Cognixion. "It validates the potential of our technology to make a real difference in the lives of individuals with severe motor impairments and underscores the importance of how AI can be used to assist people in everyday situations. We are excited to continue our work to bring this life-changing technology to those who need it most."
While a number of neurotech companies are developing invasive BCI technologies including Elon Musk’s Neuralink aimed at assisting patients with communication abilities, Cognixion’s device could be prescribed and utilized without the need for surgical procedures or significant training, providing a new level of independence and autonomy to individuals who have been unable to communicate effectively due to their conditions. With planned further development, Cognixion ONE could become a one-of-a-kind platform, aggregating additional inputs to restore life changing abilities that have been lost to people with loss of language or personal agency.
About Cognixion®
Cognixion is a leader in brain-computer, augmented reality, artificial intelligence and natural user interface technology. The company is dedicated to improving the lives of individuals with severe motor impairments by providing cutting-edge patented technology that allows them to independently communicate and interact with the world around them. The Cognixion ONE™ device is the company's flagship product, and it has already received significant recognition for its design and potential to transform the lives of individuals with severe motor impairments.
Contact:
Media
Meaghan Azlein, Marketing Manager
Investor Relations
Chris Ullrich
Cognixion
24 East Cota Street, Suite 101
Santa Barbara, CA 93101